Association of a TGF-β1 gene -509 C/T polymorphism with breast cancer risk: a meta-analysis.

abstract：:Resistance of breast cancers to targeted hormone receptor (HR) or human epidermal growth factor receptor 2 (HER2) inhibitors often occurs through dysregulation of the phosphoinositide 3-kinase, protein kinase B/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Presently, no targeted therapies exist for breast...

journal_title：Breast cancer research and treatment

authors： Wilson-Edell KA,Yevtushenko MA,Rothschild DE,Rogers AN,Benz CC

更新日期：2014-04-01 00:00:00

abstract：:The development of recombinant vaccines for specific immunotherapy of carcinoma represents a novel approach for the treatment of breast cancer and other tumor types. This article reviews the various parameters that should be considered in the development of recombinant vaccines. Several breast cancer associated antige...

journal_title：Breast cancer research and treatment

authors： Schlom J,Kantor J,Abrams S,Tsang KY,Panicali D,Hamilton JM

更新日期：1996-01-01 00:00:00

abstract：:MicroRNAs play a role in breast cancer development and progression by post-transcriptional repression of the expression of important genes, such as the tumor suppressor gene phosphatase and tensin homolog (PTEN). The focus of the current study was to examine the diagnostic potential of circulating cell-free microRNAs ...

journal_title：Breast cancer research and treatment

authors： Schwarzenbach H,Milde-Langosch K,Steinbach B,Müller V,Pantel K

更新日期：2012-08-01 00:00:00

abstract：:The population-based Ontario Breast Screening Program (OBSP) provides two-yearly screening by both nurse examiner clinical breast examination (CBE) and two-view mammography to women aged 50 to 69. CBE alone accounts for about 5% of cancer detection. The purpose of this study was to determine whether CBE information af...

journal_title：Breast cancer research and treatment

authors： Knight JA,Libstug AR,Moravan V,Boyd NF

更新日期：1998-03-01 00:00:00

abstract：BACKGROUND:Anastrozole, a new aromatase inhibitor, has been used to treat postmenopausal metastatic breast cancer, and several clinical trials of adjuvant treatment using this agent are ongoing. However, the effects of anastrozole on lipid metabolism are unknown. The aim of this study was to evaluate the effect of anas...

journal_title：Breast cancer research and treatment

authors： Hozumi Y,Hakamata Y,Sasanuma H,Ogura S,Nagai H

更新日期：2002-11-01 00:00:00

abstract：:There remains a high unmet need for effective treatments for metastatic breast cancer. In recent years there have been many advances in the understanding of biological basis of cancer. Several cellular pathways have been identified that play crucial roles in causing or maintaining the cancer phenotype. Many new agents...

journal_title：Breast cancer research and treatment

authors： Roy V,Perez EA

更新日期：2009-07-01 00:00:00

abstract：:We have compared by RNA in situ hybridisation on serial cryo-sections the distribution of cathepsin D (cathD), stromelysin 3 (strom-3), and urokinase plasminogen activator (UPA) gene expression in different tissues of human benign and malignant mammary tumors. Cath-D expression was found to be higher in adenocarcinoma...

journal_title：Breast cancer research and treatment

authors： Escot C,Zhao Y,Puech C,Rochefort H

更新日期：1996-01-01 00:00:00

abstract：:The aim of this study is to identify and validate copy number aberrations in early-stage primary breast tumors associated with bone or non-bone metastasis. Whole-genome molecular inversion probe arrays were used to evaluate copy number imbalances (CNIs) in breast tumors from 960 early-stage patients with information a...

journal_title：Breast cancer research and treatment

authors： Liu Y,Zhou R,Baumbusch LO,Tsavachidis S,Brewster AM,Do KA,Sahin A,Hortobagyi GN,Taube JH,Mani SA,Aarøe J,Wärnberg F,Børresen-Dale AL,Mills GB,Thompson PA,Bondy ML

更新日期：2014-01-01 00:00:00

abstract：PURPOSE:Inflammatory breast cancer (IBC) is the most aggressive form of locally advanced breast cancer (LABC). The IBC phenotype is characterized by an infiltrative growth pattern, increased (lymph)angiogenesis and the propensity to invade dermal lymphatics. In pancreatic cancer, interactions between caveolin-1 and Rho...

journal_title：Breast cancer research and treatment

authors： Van den Eynden GG,Van Laere SJ,Van der Auwera I,Merajver SD,Van Marck EA,van Dam P,Vermeulen PB,Dirix LY,van Golen KL

更新日期：2006-02-01 00:00:00

abstract：PURPOSE:The purpose of this research was to generate recommendations on strategies to achieve patient-centered care (PCC) for ductal carcinoma in situ (DCIS). METHODS:Thirty clinicians (surgeons, medical/radiation oncologists, radiologists, nurses, navigators) who manage DCIS and 32 DCIS survivors aged 18 or older wer...

journal_title：Breast cancer research and treatment

authors： Gagliardi AR,Wright FC,Look Hong NJ,Groot G,Helyer L,Meiers P,Quan ML,Urquhart R,Warburton R

更新日期：2019-04-01 00:00:00

abstract：:Screening of a breast cancer cDNA library from SKBR3 human breast cancer cells by SEREX (serological analysis of cDNA expression library) using a preselected serum from a breast cancer patient revealed 13 genes, two of which, INT-MI-1 and INT-MI-2, encode novel gene products, while the remaining 11 genes and their pro...

journal_title：Breast cancer research and treatment

authors： Forti S,Scanlan MJ,Invernizzi A,Castiglioni F,Pupa S,Agresti R,Fontanelli R,Morelli D,Old LJ,Pupa SM,Ménard S

更新日期：2002-06-01 00:00:00

abstract：BACKGROUND:Adjuvant therapy decisions may be partly based on the results of a multigene quantitative reverse transcription-polymerase chain reaction (RT-PCR)-based assay: the 21-gene recurrence score (RS) test of resection specimens. When necessary, core needle biopsy (CNB) may be considered as a surrogate. Here, we ev...

journal_title：Breast cancer research and treatment

authors： Qi P,Yang Y,Bai QM,Xue T,Ren M,Yao QL,Yang WT,Zhou XY

更新日期：2021-01-13 00:00:00

abstract：:Magnetic nanoparticles (MNPs) possess unique properties, which make them highly attractive for medical applications. The use of MNPs in surgery has mainly been focused on their role in the identification of metastatic lymph node involvement. There have been developments within this field, including ongoing and newly c...

journal_title：Breast cancer research and treatment

authors： Ahmed M,Douek M

更新日期：2014-01-01 00:00:00

abstract：:The proportional hazards model is frequently used in analyzing the results of clinical trials, when it is often the case that the outcomes are right-censored. This model allows one to measure treatment effects and simultaneously identify and adjust for prognostic factors that might influence the outcome. In this paper...

journal_title：Breast cancer research and treatment

authors： Hastie T,Sleeper L,Tibshirani R

更新日期：1992-01-01 00:00:00

abstract：:Estrogen receptor protein is known to be an important prognostic factor for patients with breast cancer. The presence of estrogen receptor correlates with response to endocrine therapy in patients with metastatic disease and is associated with prolonged disease-free and overall survival in patients with primary diseas...

journal_title：Breast cancer research and treatment

authors： Clark GM,McGuire WL

更新日期：1983-01-01 00:00:00

abstract：:Genetic testing enables women at risk for hereditary breast and/or ovarian cancer to find out whether they have inherited the gene mutation (BRCA1/BRCA2), and if so, to opt for frequent surveillance and/or prophylactic surgery (bilateral mastectomy and/or oophorectomy). Here, a follow-up is described for 63 healthy wo...

journal_title：Breast cancer research and treatment

authors： Lodder LN,Frets PG,Trijsburg RW,Meijers-Heijboer EJ,Klijn JG,Seynaeve C,van Geel AN,Tilanus MM,Bartels CC,Verhoog LC,Brekelmans CT,Burger CW,Niermeijer MF

更新日期：2002-05-01 00:00:00

abstract：PURPOSE:Tumour budding (TB) is an adverse histological feature in many epithelial cancers. It is thought to represent epithelial-mesenchymal transition, a key step in the metastatic process. The significance of TB in breast carcinoma (BC) remains unclear. The aim of this study is to investigate the relationship between...

journal_title：Breast cancer research and treatment

authors： Lloyd AJ,Ryan ÉJ,Boland MR,Elwahab SA,Malone C,Sweeney KJ,Barry KM,McLaughlin R,Kerin MJ,Lowery AJ

更新日期：2020-10-01 00:00:00

abstract：:Fat necrosis of the breast is increasingly reported and used as a trial endpoint in the treatment of breast cancer with accelerated partial breast irradiation (APBI). Yet, there is no universal toxicity scoring system within the latest version of the Common Terminology Criteria for Adverse Events (CTCAE v4.0). This re...

journal_title：Breast cancer research and treatment

authors： Russo AL,Taghian AG

更新日期：2013-07-01 00:00:00

abstract：:The effect of 17-beta-estradiol (E2) on the induction of osteolytic lesions by estrogen receptor (ER)-negative breast cancer cells was investigated in 4-week-old female nude mice. Exposure to exogenous E2 was found to increase osteolytic areas on radiographs up to 5.3 times in mice inoculated intracardially with MDA-2...

journal_title：Breast cancer research and treatment

authors： Winding B,Misander H,Høegh-Andersen P,Brünner N,Foged NT

更新日期：2003-03-01 00:00:00

abstract：RATIONALE:Survival after loco-regional failure (LRF) of breast cancer was investigated at the population level. METHODS:Using the Stockholm cancer registry, 2698 patients diagnosed with LRF between 1980 and 2014 were identified and divided into three cohorts by year of LRF diagnosis. Post-relapse event-free survival (...

journal_title：Breast cancer research and treatment

authors： Falato C,Taylor SK,Szulkin R,Nordblom A,Eriksson L,Sofiadis A,Fredriksson I,Hartman J,Bergh J,Foukakis T

更新日期：2018-12-01 00:00:00

abstract：:Mucinous breast cancer (MBC) is mainly a disease of postmenopausal women. Pure MBC is rare and augurs a good prognosis. In contrast, MBC mixed with other histological subtypes of invasive disease loses the more favorable prognosis. Because of the relative rarity of pure MBC, little is known about its cell and tumor bi...

journal_title：Breast cancer research and treatment

authors： Jambal P,Badtke MM,Harrell JC,Borges VF,Post MD,Sollender GE,Spillman MA,Horwitz KB,Jacobsen BM

更新日期：2013-01-01 00:00:00

abstract：:Since germline mutations in the PALB2 (Partner and Localizer of BRCA2) gene have been identified as breast cancer (BC) susceptibility alleles, the geographical spread and risks associated with PALB2 mutations are subject of intense investigation. Patients with bilateral breast cancer constitute a valuable group for ge...

journal_title：Breast cancer research and treatment

authors： Bogdanova N,Sokolenko AP,Iyevleva AG,Abysheva SN,Blaut M,Bremer M,Christiansen H,Rave-Fränk M,Dörk T,Imyanitov EN

更新日期：2011-04-01 00:00:00

abstract：:The expression of amphiregulin (AR), heregulin (HRG), and cripto-1 (CR-1) mRNA transcripts was assessed in 60 human primary breast carcinoma. AR and HRG transcripts were expressed respectively in 58% and 25% of the carcinomas as measured by Northern blot analysis. CR-1 mRNA was found in 77% of the carcinomas using Rev...

journal_title：Breast cancer research and treatment

authors： Normanno N,Kim N,Wen D,Smith K,Harris AL,Plowman G,Colletta G,Ciardiello F,Salomon DS

更新日期：1995-09-01 00:00:00

abstract：:The concept of cancer cells being hierarchically organized and arising from their own progenitor stem cells will have important implications on cancer therapy. If this hypothesis were to be true then the paucity of estrogen receptors in stem cells as well as their inherent drug resistance mechanisms pose a challenge t...

journal_title：Breast cancer research and treatment

authors： Resetkova E,Reis-Filho JS,Jain RK,Mehta R,Thorat MA,Nakshatri H,Badve S

更新日期：2010-08-01 00:00:00

abstract：PURPOSE:The receptor activator of nuclear factor kappa B (RANK)/RANK ligand (RANKL)/osteoprotegerin (OPG) axis may contribute to the development of bone metastases (BM). We studied gene expression in this pathway in primary breast cancer (BC) to determine correlations with clinical characteristics and outcomes in the n...

journal_title：Breast cancer research and treatment

authors： Vidula N,Yau C,Li J,Esserman LJ,Rugo HS

更新日期：2017-08-01 00:00:00

abstract：PURPOSE:There is a need for biomarkers of drug efficacy for targeted therapies in triple-negative breast cancer (TNBC). As a step toward this, we identify multi-omic molecular determinants of anti-TNBC efficacy in cell lines for a panel of oncology drugs. METHODS:Using 23 TNBC cell lines, drug sensitivity scores (DSS3...

journal_title：Breast cancer research and treatment

authors： Merrill NM,Lachacz EJ,Vandecan NM,Ulintz PJ,Bao L,Lloyd JP,Yates JA,Morikawa A,Merajver SD,Soellner MB

更新日期：2020-01-01 00:00:00

abstract：:We conducted gene-based analysis in 26 genes in the FGFR signaling pathway to identify genes carrying genetic variation affecting risk of breast cancer and the specific estrogen receptor (ER) subtypes. Tagging single-nucleotide polymorphisms (SNPs) for each gene were selected and genotyped on a customized Illumina Exo...

journal_title：Breast cancer research and treatment

authors： Ruiz-Narváez EA,Haddad SA,Lunetta KL,Yao S,Bensen JT,Sucheston-Campbell LE,Hong CC,Haiman CA,Olshan AF,Ambrosone CB,Palmer JR

更新日期：2016-01-01 00:00:00

abstract：:The proto-oncogene, HER2, has prognostic and predictive relevance in invasive breast cancer (IBC). HER2 testing of primary IBC guides treatment selection and is assumed to reflect HER2 status of associated metastases, although HER2 discordance between IBC and metastasis has been reported. Systematic review and meta-an...

journal_title：Breast cancer research and treatment

authors： Houssami N,Macaskill P,Balleine RL,Bilous M,Pegram MD

更新日期：2011-10-01 00:00:00

abstract：:We investigated the role of glial cell line-derived neurotrophic factor (GDNF) in compensating trastuzumab (TZMB)-induced apoptosis in HER2+ breast cancer (BC) cells using xenograft tumors. We generated BC xenografts in nude mice using samples from three patients selected based on their HER2 status and response to TZM...

journal_title：Breast cancer research and treatment

authors： Gardaneh M,Shojaei S,Kaviani A,Behnam B

更新日期：2017-04-01 00:00:00

abstract：AIMS:To investigate the efficacy of letrozole 2.5 mg and 10 mg used as primary neoadjuvant therapy for patients with locally advanced and large operable breast cancer. PATIENTS AND METHODS:Twenty-four postmenopausal patients with locally advanced or large operable breast cancer were treated in two consecutive series w...

journal_title：Breast cancer research and treatment

authors： Dixon JM,Love CD,Bellamy CO,Cameron DA,Leonard RC,Smith H,Miller WR

更新日期：2001-04-01 00:00:00